Organon’s second quarter brought flat year-on-year revenue, outpacing Wall Street’s expectations, but the market responded negatively to the results. Management cited headwinds from the loss of exclusivity for Atozet in Europe, pricing pressures on mature products, and federal funding uncertainties affecting Nexplanon’s U.S. performance. CEO Kevin Ali acknowledged, “There is a little bit of hesitancy, especially around the Planned Parenthood issues that are there that needs to be dealt with.” The company also focused on cost controls, debt reduction, and operational discipline to offset margin contraction.
Is now the time to buy OGN? Find out in our full research report (it’s free).
Organon (OGN) Q2 CY2025 Highlights:
- Revenue: $1.59 billion vs analyst estimates of $1.55 billion (flat year on year, 2.8% beat)
- Adjusted EPS: $1 vs analyst estimates of $0.94 (6.4% beat)
- Adjusted EBITDA: $522 million vs analyst estimates of $475.3 million (32.7% margin, 9.8% beat)
- Operating Margin: 20.3%, down from 23.1% in the same quarter last year
- Market Capitalization: $2.35 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Organon’s Q2 Earnings Call
- Alexandra Doering von Riesemann (Piper Sandler) asked about incremental sales and marketing investment for Vtama and the number of sales reps. CEO Kevin Ali explained new investments in telehealth, DTC campaigns, and sales force expansion, noting over 125 reps now support Vtama.
- Michael Thomas Nedelcovych (TD Cowen) pressed for details on U.S. Nexplanon headwinds and capital allocation priorities. Ali detailed U.S. funding uncertainty affecting Nexplanon, but expressed confidence in growth as planned funding issues resolve and the five-year indication launches.
- Terence C. Flynn (Morgan Stanley) questioned the impact of potential EU tariffs on 2026 margins and free cash flow trends. CFO Matthew Walsh indicated it’s too early to quantify tariff effects for 2026, but stated free cash flow should grow as one-time costs decline.
- Umer Raffat (Evercore) sought clarity on Vtama’s prescription volume trajectory and management’s strategy to accelerate growth. Ali pointed to recent investments in access and marketing, and expects improved coverage and sales force expansion to drive volume gains.
- Jason Matthew Gerberry (Bank of America) asked about discontinuation of endometriosis R&D programs and the regulatory outlook for generic Nexplanon. Head of R&D Juan Camilo Arjona Ferreira confirmed the discontinuation of the backup molecule and said the FDA will determine requirements for generics, as Organon focuses on launching the five-year Nexplanon indication.
Catalysts in Upcoming Quarters
Looking forward, the StockStory team will monitor (1) the adoption and payer coverage expansion for Vtama, especially in pediatric and international markets, (2) the successful U.S. launch and uptake of the five-year Nexplanon indication as funding uncertainties resolve, and (3) continued progress in biosimilars, particularly the rollout of Tofidence and future Henlius products. Execution on margin improvement and debt reduction will also be key signposts for Organon’s strategic progress.
Organon currently trades at $9.11, down from $9.67 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).
Our Favorite Stocks Right Now
Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.
The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
